One World Pharmaceuticals

Our Vision and Mission

Here at One World Pharmaceuticals (OWP), we envision a world where all individuals, regardless of their location or background, have access to top-tier medical and pharmaceutical care. Our founder and president, Scott Boyer, have instilled in us the commitment to support healthcare providers and patients in the United States with high-quality medications. We take this a step further by donating our profits to ROW Global, a non-profit organization dedicated to enhancing the education, diagnosis, and treatment of neurological disorders in under-resourced regions worldwide. Essentially, OWP harnesses commercial success for the greater good, championing humanitarian projects across various countries.

ROW Global Health

ROW Global Health is at the core of our purpose. We are dedicated to improving global health by providing essential medications and supporting initiatives that aim to alleviate the burden of neurological disorders in underprivileged communities. By collaborating with ROW Global, we ensure that our profits contribute to making a significant difference in the lives of those who need it most.

OWP Starter Kits

OWP currently offers Subvenite (lamotrigine tablets, USP) Starter Kits, which serve as our branded generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits. Additionally, we market Lamotrigine Starter Kits, the generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits. With three distinct Starter Kits (Orange, Blue, and Green) based on FDA-approved 5-week titration schedules, OWP caters to patients initiating lamotrigine therapy.

Subvenite Important Safety Information

WARNING: SERIOUS SKIN RASHES

Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been attributed to lamotrigine, which may result in life-threatening consequences. These severe rashes occur more frequently in pediatric patients than in adults. Specific factors that increase the risk of rash include coadministration with valproate, exceeding the recommended initial dose of SUBVENITE, and exceeding the recommended dose escalation of SUBVENITE. It is important to note that benign rashes may also be caused by lamotrigine; however, predicting which rashes will become life-threatening is not possible. Upon the emergence of the first sign of rash, SUBVENITE should be discontinued unless it is evident that the rash is not drug-related.

Please refer to the complete Prescribing Information for SUBVENITE (lamotrigine tablets, USP) for the full boxed warning.

SUBVENITE is used to treat the following conditions:

1. Epilepsy (adjunctive therapy): For patients aged 2 years and older, SUBVENITE is indicated for the following seizure types:

• Partial-onset seizures
• Primary generalized tonic-clonic seizures
• Generalized seizures of Lennox-Gastaut syndrome.

2. Epilepsy (monotherapy): For patients aged 16 years and older, SUBVENITE is prescribed for conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug.

3. Bipolar disorder (maintenance treatment): SUBVENITE is intended for maintaining the treatment of bipolar I disorder, delaying the time to occurrence of mood episodes in patients who have been treated for acute mood episodes with standard therapy.

LIMITATIONS OF USE: Treatment of acute manic or mixed episodes is not recommended. The efficacy of SUBVENITE in the acute treatment of mood episodes has not been established.

CONTRAINDICATIONS: SUBVENITE is contraindicated in patients who have previously exhibited hypersensitivity to the drug or its components.

WARNINGS & PRECAUTIONS: The potential for life-threatening serious rashes, HLH (hemophagocytic lymphohistiocytosis), DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), systemic inflammation, fever, and rash should be carefully monitored in patients receiving SUBVENITE. A prompt and accurate diagnosis of HLH and DRESS is crucial for treatment.